Fig. 5

METTL3 accelerates HNSCC malignant progression by upregulating CDC25B. A Colony formation assay of METTL3 overexpressing Hep2 cells transfected with CDC25B siRNAs and the corresponding control (left panel), numbers of the colony formation were calculated (right panel). B Colony formation assay of METTL3 overexpressing Hep2 cells treated with 5 μM menadione or DMSO for 24 h (left panel), numbers of the colony formation were calculated (right panel). C Transwell assay of METTL3 overexpressing Hep2 cells transfected with CDC25B siRNAs and the corresponding control (left panel) to evaluate cell migration and invasion ability (scale bars = 100 μm, left panel), numbers of cells migrated and invaded were calculated (right panel). D Transwell assay of METTL3 overexpressing Hep2 cells treated with 5 μM menadione or DMOS for 24 h and the corresponding control (scale bars = 100 μm, left panel), numbers of cells migrated and invaded were calculated (right panel). E Cell cycle assay of METTL3 overexpressing Hep2 cells transfected with CDC25B siRNAs and the corresponding control (left panel), percentage of cell cycle phase was calculated (right panel). F Cell cycle assay of METTL3 overexpressing Hep2 cells treated with 5 μM menadione or DMSO for 24 h and the corresponding control (left panel), percentage of cell cycle phase was calculated (right panel). The data are the means ± SD of three independent experiments. * p < 0.05; ** p < 0.01